-$0.17 EPS Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter

Brokerages forecast that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will report ($0.17) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Ironwood Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.35). Ironwood Pharmaceuticals reported earnings per share of ($0.14) during the same quarter last year, which would indicate a negative year-over-year growth rate of 21.4%. The company is expected to issue its next quarterly earnings report before the market opens on Wednesday, February 13th.

According to Zacks, analysts expect that Ironwood Pharmaceuticals will report full-year earnings of ($1.06) per share for the current year, with EPS estimates ranging from ($1.09) to ($1.02). For the next year, analysts anticipate that the business will report earnings of $0.23 per share, with EPS estimates ranging from ($0.12) to $0.72. Zacks’ earnings per share averages are an average based on a survey of analysts that that provide coverage for Ironwood Pharmaceuticals.

Several brokerages recently issued reports on IRWD. Zacks Investment Research raised Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, January 28th. BidaskClub raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, January 31st. HC Wainwright set a $13.00 target price on Ironwood Pharmaceuticals and gave the company a “sell” rating in a research report on Wednesday, October 31st. ValuEngine cut Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, December 12th. Finally, Wood & Company reaffirmed a “buy” rating on shares of Ironwood Pharmaceuticals in a research report on Thursday, January 31st. Two analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company. Ironwood Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $17.28.



Shares of NASDAQ:IRWD traded down $0.18 during mid-day trading on Wednesday, hitting $13.69. 101,107 shares of the company traded hands, compared to its average volume of 1,380,053. The stock has a market cap of $2.14 billion, a price-to-earnings ratio of -14.74 and a beta of 1.91. Ironwood Pharmaceuticals has a 12-month low of $9.07 and a 12-month high of $21.20.

In other Ironwood Pharmaceuticals news, CEO Peter M. Hecht sold 30,000 shares of the business’s stock in a transaction on Wednesday, January 23rd. The stock was sold at an average price of $12.66, for a total value of $379,800.00. Following the sale, the chief executive officer now directly owns 4,726,917 shares in the company, valued at $59,842,769.22. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Peter M. Hecht sold 89,551 shares of the business’s stock in a transaction on Friday, January 25th. The shares were sold at an average price of $12.53, for a total value of $1,122,074.03. Following the completion of the sale, the chief executive officer now owns 4,726,917 shares in the company, valued at $59,228,270.01. The disclosure for this sale can be found here. Insiders have sold 121,551 shares of company stock worth $1,526,814 over the last quarter. 7.63% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of IRWD. CWM LLC bought a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at $31,000. First Manhattan Co. bought a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at $133,000. Bank of Montreal Can raised its stake in shares of Ironwood Pharmaceuticals by 426.9% in the fourth quarter. Bank of Montreal Can now owns 16,846 shares of the biotechnology company’s stock valued at $175,000 after buying an additional 13,649 shares during the period. Pacer Advisors Inc. bought a new stake in shares of Ironwood Pharmaceuticals in the third quarter valued at $177,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Ironwood Pharmaceuticals in the third quarter valued at $249,000. Hedge funds and other institutional investors own 93.85% of the company’s stock.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.

Further Reading: What is a back-end load?

Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply